Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors
Authors:
- Priyanka SwamiPSPriyanka Swami
- Kelly A. O’connellKOKelly A. O’connell
- Swetha ThiyagarajanSTSwetha Thiyagarajan
- Ayrianne CrawfordACAyrianne Crawford
- Prathamesh PatilPPPrathamesh Patil
- Prakash RadhakrishnanPRPrakash Radhakrishnan
- Simon ShinSSSimon Shin
- Thomas C. CaffreyTCThomas C. Caffrey
- James GrunkemeyerJGJames Grunkemeyer
- Tammi NevilleTNTammi Neville
- Stefan W. VetterSVStefan W. Vetter
- Michael A. HollingsworthMHMichael A. Hollingsworth
Open Access
- 1 April 2021
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (4) , 526
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a very difficult cancer to treat. Recent in vitro and in vivo studies suggest that the activation of the receptor for advanced glycation end products (RAGE) by its ligands stimulates pancreatic cancer cell proliferation and tumor growth. Additional studies show that, in the RAGE ligand, the high mobility group box 1 (HMGB1) protein plays an important role in chemoresistance against the cytotoxic agent gemcitabine by promoting cell survival through increased autophagy. We hypothesized that blocking the RAGE/HMGB1 interaction would enhance the cytotoxic effect of gemcitabine by reducing cell survival and autophagy. Using a preclinical mouse model of PDAC and a monoclonal antibody (IgG 2A11) as a RAGE inhibitor, we demonstrate that RAGE inhibition concurrent with gemcitabine treatment enhanced the cytotoxic effect of gemcitabine. The combination of IgG 2A11 and gemcitabine resulted in decreased autophagy compared to treatment with gemcitabine combined with control antibodies. Notably, we also observed that RAGE inhibition protected against excessive weight loss during treatment with gemcitabine. Our data suggest that the combination of gemcitabine with a RAGE inhibitor could be a promising therapeutic approach for the treatment of pancreatic cancer and needs to be further investigated.Keywords
Funding Information
- National Institute of General Medical Sciences (P30GM103332, P20GM109024)
This publication has 95 references indexed in Scilit:
- Receptor for Advanced Glycation End Products (RAGE) Functions as Receptor for Specific Sulfated Glycosaminoglycans, and Anti-RAGE Antibody or Sulfated Glycosaminoglycans Delivered in Vivo Inhibit Pulmonary Metastasis of Tumor CellsJournal of Biological Chemistry, 2012
- Deconvoluting the context-dependent role for autophagy in cancerNature Reviews Cancer, 2012
- The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasiaProceedings of the National Academy of Sciences, 2012
- Lack of an Endogenous Anti-inflammatory Protein in Mice Enhances Colonization of B16F10 Melanoma Cells in the LungsJournal of Biological Chemistry, 2010
- High-mobility group box 1 and cancerBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Binding of S100 proteins to RAGE: An updateBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammationAnnals of Medicine, 2009
- Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosisBiochemical Pharmacology, 2008
- RAGE signaling sustains inflammation and promotes tumor developmentJournal of Experimental Medicine, 2008
- Autophagy in the Pathogenesis of DiseaseCell, 2008